T-regulatory/T-helper 17: Promiscuous signals and fear of commitment

Danielle Tartar, Amie M. Van Morlan, Habib Zaghouani

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cells, under the guidance of environmental signals, follow a one-way road to evolve as Th1, Th2, Th17 or regulatory T cells (Tregs). The current paper, however, demonstrates a crosstalk between signals and identifies transitory T-cell states whereby a differentiating CD4 + T cell will express a mixed Th17 and Treg phenotype. Moreover, they were able to successfully reprogram terminally differentiated Tregs into Th17 cells, suggesting that differentiation could occur and provides an environmental plasticity to readjust immunity. This suggests that T-cell differentiation does not necessarily follow a one-way road, but that traffic may flow in both directions.

Original languageEnglish (US)
Pages (from-to)27-29
Number of pages3
JournalImmunotherapy
Volume1
Issue number1
DOIs
StatePublished - Dec 28 2009
Externally publishedYes

Fingerprint

Fear
T-Lymphocytes
Cell Differentiation
Th17 Cells
Regulatory T-Lymphocytes
Immunity
Transcription Factors
Cytokines
Phenotype

Keywords

  • T-helper 17
  • T-helper cell differentiation
  • T-regulatory cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

T-regulatory/T-helper 17 : Promiscuous signals and fear of commitment. / Tartar, Danielle; Van Morlan, Amie M.; Zaghouani, Habib.

In: Immunotherapy, Vol. 1, No. 1, 28.12.2009, p. 27-29.

Research output: Contribution to journalComment/debate

Tartar, Danielle ; Van Morlan, Amie M. ; Zaghouani, Habib. / T-regulatory/T-helper 17 : Promiscuous signals and fear of commitment. In: Immunotherapy. 2009 ; Vol. 1, No. 1. pp. 27-29.
@article{1450ea3c0cd6412db048f71c624df4c6,
title = "T-regulatory/T-helper 17: Promiscuous signals and fear of commitment",
abstract = "The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cells, under the guidance of environmental signals, follow a one-way road to evolve as Th1, Th2, Th17 or regulatory T cells (Tregs). The current paper, however, demonstrates a crosstalk between signals and identifies transitory T-cell states whereby a differentiating CD4 + T cell will express a mixed Th17 and Treg phenotype. Moreover, they were able to successfully reprogram terminally differentiated Tregs into Th17 cells, suggesting that differentiation could occur and provides an environmental plasticity to readjust immunity. This suggests that T-cell differentiation does not necessarily follow a one-way road, but that traffic may flow in both directions.",
keywords = "T-helper 17, T-helper cell differentiation, T-regulatory cell",
author = "Danielle Tartar and {Van Morlan}, {Amie M.} and Habib Zaghouani",
year = "2009",
month = "12",
day = "28",
doi = "10.2217/1750743X.1.1.27",
language = "English (US)",
volume = "1",
pages = "27--29",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - T-regulatory/T-helper 17

T2 - Promiscuous signals and fear of commitment

AU - Tartar, Danielle

AU - Van Morlan, Amie M.

AU - Zaghouani, Habib

PY - 2009/12/28

Y1 - 2009/12/28

N2 - The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cells, under the guidance of environmental signals, follow a one-way road to evolve as Th1, Th2, Th17 or regulatory T cells (Tregs). The current paper, however, demonstrates a crosstalk between signals and identifies transitory T-cell states whereby a differentiating CD4 + T cell will express a mixed Th17 and Treg phenotype. Moreover, they were able to successfully reprogram terminally differentiated Tregs into Th17 cells, suggesting that differentiation could occur and provides an environmental plasticity to readjust immunity. This suggests that T-cell differentiation does not necessarily follow a one-way road, but that traffic may flow in both directions.

AB - The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cells, under the guidance of environmental signals, follow a one-way road to evolve as Th1, Th2, Th17 or regulatory T cells (Tregs). The current paper, however, demonstrates a crosstalk between signals and identifies transitory T-cell states whereby a differentiating CD4 + T cell will express a mixed Th17 and Treg phenotype. Moreover, they were able to successfully reprogram terminally differentiated Tregs into Th17 cells, suggesting that differentiation could occur and provides an environmental plasticity to readjust immunity. This suggests that T-cell differentiation does not necessarily follow a one-way road, but that traffic may flow in both directions.

KW - T-helper 17

KW - T-helper cell differentiation

KW - T-regulatory cell

UR - http://www.scopus.com/inward/record.url?scp=77953427817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953427817&partnerID=8YFLogxK

U2 - 10.2217/1750743X.1.1.27

DO - 10.2217/1750743X.1.1.27

M3 - Comment/debate

C2 - 20635970

AN - SCOPUS:77953427817

VL - 1

SP - 27

EP - 29

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 1

ER -